Those with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasias should not use these drugs
The Science Behind This Combination Understanding why this stack works requires looking at how fat loss happens at a cellular level and where each peptide intervenes in that process
How the Three Pathways Work Together What makes the design work is that the three receptor pathways complement each other: GLP-1 reduces energy intake (you eat less) GIP optimizes how that energy is used (better insulin sensitivity, favorable fat distribution) Glucagon increases energy expenditure (you burn more calories at rest and mobilize stored fat) The net effect: you eat less, your body uses energy more efficiently, and you burn more calories at rest
Die wissenschaftliche und klinische Relevanz von Retatrutide sttzt sich unter anderem auf die vielbeachtete Phase-2-Studie von Jastreboff et al., die 2023 im renommierten New England Journal of Medicine (NEJM) verffentlicht wurde (PubMed-ID: 37385275)
For additional perspective, heres a list of more studies that show the same: A potential link between liraglutide and thyroid cancer (along with pancreatic and gallbladder problems as well) (3) Study highlighting that liraglutide should not be used in people with a family history of medullary thyroid cancer (4) A study showing there is no increase in the risk of thyroid cancer (for additional perspective) (5) A meta-analysis showing that there is not enough evidence to suggest there is a link between thyroid cancer and GLP-1 agonists (6) Its worth pointing out that while there is still debate on this topic, the larger and bigger studies on this issue seem to support a connection between the two
10.1016/S0140-6736(15)00803-X 3 ArvanitakisK.KoufakisT.KotsaK.GermanidisG
